1383 related articles for article (PubMed ID: 26574232)
1. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
[TBL] [Abstract][Full Text] [Related]
2. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation.
Ruf S; Behnke-Hall K; Gruhn B; Bauer J; Horn M; Beck J; Reiter A; Wagner HJ
J Clin Virol; 2012 Mar; 53(3):186-94. PubMed ID: 22182950
[TBL] [Abstract][Full Text] [Related]
3. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M
Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566
[TBL] [Abstract][Full Text] [Related]
5. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
6. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
7. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
Fellner MD; Durand KA; Solernou V; Bosaleh A; Balbarrey Z; García de Dávila MT; Rodríguez M; Irazu L; Alonio LV; Picconi MA
Rev Argent Microbiol; 2016; 48(2):110-8. PubMed ID: 27157146
[TBL] [Abstract][Full Text] [Related]
9. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
Lee TC; Savoldo B; Barshes NR; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Scott JD; Goss JA
Clin Transplant; 2006; 20(3):389-93. PubMed ID: 16824159
[TBL] [Abstract][Full Text] [Related]
10. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients.
Merlino C; Cavallo R; Bergallo M; Giacchino F; Bollero C; Negro Ponzi A; Cavallo G
New Microbiol; 2003 Apr; 26(2):141-9. PubMed ID: 12737195
[TBL] [Abstract][Full Text] [Related]
11. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?
Solano C; Mateo EM; Pérez A; Talaya A; Terol MJ; Albert E; Giménez E; Vinuesa V; Piñana JL; Boluda JCH; Navarro D
J Clin Virol; 2017 Dec; 97():26-32. PubMed ID: 29096390
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT.
Kinch A; Hallböök H; Arvidson J; Sällström K; Bondeson K; Pauksens K
Leuk Lymphoma; 2018 May; 59(5):1172-1179. PubMed ID: 28831836
[TBL] [Abstract][Full Text] [Related]
14. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation.
Kim BK; Kang HJ; Hong KT; An HY; Choi JY; Lee JS; Park SS; Shin HY
Transpl Infect Dis; 2019 Dec; 21(6):e13182. PubMed ID: 31556214
[TBL] [Abstract][Full Text] [Related]
15. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of measuring Epstein-Barr virus-specific cell-mediated immunity after HSCT in addition to virological monitoring: results from a prospective study.
Chiereghin A; Piccirilli G; Belotti T; Prete A; Bertuzzi C; Gibertoni D; Gabrielli L; Turello G; Borgatti EC; Barbato F; Sessa M; Arpinati M; Bonifazi F; Lazzarotto T
Med Microbiol Immunol; 2019 Dec; 208(6):825-834. PubMed ID: 31289930
[TBL] [Abstract][Full Text] [Related]
17. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
[TBL] [Abstract][Full Text] [Related]
18. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation.
Chen HS; Ho MC; Hu RH; Wu JF; Chen HL; Ni YH; Hsu HY; Jeng YM; Chang MH
J Formos Med Assoc; 2019 Sep; 118(9):1362-1368. PubMed ID: 30612881
[TBL] [Abstract][Full Text] [Related]
19. The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients.
Wareham NE; Mocroft A; Sengeløv H; Da Cunha-Bang C; Gustafsson F; Heilmann C; Iversen M; Kirkby NS; Rasmussen A; Sørensen SS; Lundgren JD;
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1569-1580. PubMed ID: 29804164
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.
Patriarca F; Medeot M; Isola M; Battista ML; Sperotto A; Pipan C; Toffoletti E; Dozzo M; Michelutti A; Gregoraci G; Geromin A; Cerno M; Savignano C; Rinaldi C; Barbone F; Fanin R
Transpl Infect Dis; 2013 Jun; 15(3):259-67. PubMed ID: 23405972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
